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Abstract
MicroRNA profiling represents an important first-step in deducting individual RNA-based regulatory function in a cell, tissue,
or at a specific developmental stage. Currently there are several different platforms to choose from in order to make the
initial miRNA profiles. In this study we investigate recently developed digital microRNA high-throughput technologies. Four
different platforms were compared including next generation SOLiD ligation sequencing and Illumina HiSeq sequencing,
hybridization-based NanoString nCounter, and miRCURY locked nucleic acid RT-qPCR. For all four technologies, full
microRNA profiles were generated from human cell lines that represent noninvasive and invasive tumorigenic breast cancer.
This study reports the correlation between platforms, as well as a more extensive analysis of the accuracy and sensitivity of
data generated when using different platforms and important consideration when verifying results by the use of additional
technologies. We found all the platforms to be highly capable for microRNA analysis. Furthermore, the two NGS platforms
and RT-qPCR all have equally high sensitivity, and the fold change accuracy is independent of individual miRNA
concentration for NGS and RT-qPCR. Based on these findings we propose new guidelines and considerations when
performing microRNA profiling.
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Introduction
MicroRNAs (miRNAs) represent a class of small non-coding
RNAs (ncRNAs), approximately 22 nucleotides (nt) in length,
which regulate the expression of target genes at the posttranscrip-
tional level [1–4]. MiRNAs contribute to important biological
processes including cellular differentiation, proliferation, and
apoptosis [5–9]. Most miRNAs regulate gene expression by
guiding effector protein complexes (RISC) through binding to
complementary sequences in the 39 untranslated region (UTR) of
mRNAs, followed by subsequent inhibition of translation or
destabilization of the target mRNA sequence [10,11]. Conserved
miRNA targets sites have been predicted in as many as two thirds
of all human mRNAs [12]. Furthermore, one specific miRNA may
target different mRNAs and one specific mRNA may be regulated
by multiple miRNAs [13–16].
Aberrant miRNA expression may have serious consequences for
the cell, and miRNA species have been found to be involved in the
initiation and progression of many human diseases, including
cancer [17,18]. This makes miRNAs interesting candidates as
biomarkers in human cancer [19–21]. Indeed, miRNA profiling
has been shown to be an important approach in the molecular
characterization of tumor subtypes and disease progression
[22,23]. Consequently, such profiling strategies can provide
important guidance in the choice of treatment strategy, which
ultimately can increase cancer patient survival [9,24].
MiRNA profiling involves the measurement of the relative
amount of expressed miRNAs in a sample [25]. There are three
major technological approaches that dominate the research field:
MiRNA profiling based on hybridization (microarrays and
nCounter) [26–28], next generation sequencing (NGS) [29], and
amplification (reverse transcription quantitative real time-PCR,
RT-qPCR) [30]. Platform comparison studies have been per-
formed by comparing miRNA expression profiles obtained by RT-
qPCR- and NGS analyses to the more cost-efficient high-
throughput microarray analyses [31–33]. These studies conclude
that RT-qPCR and NGS have better sensitivity and accuracy than
hybridization-based microarray analyses. The performance of
different NGS platforms has also been compared [34–37]. Here,
the absolute values for individual miRNAs differ between the
platforms, even though their relative abundances remain constant.
Differences in the library preparation protocols appear to be the
main reason for this discrepancy. The nCounter platform was
recently included in a comparison study where microarray,
Illumina NGS platform, and RT-qPCR were evaluated [38].
However, as in many other platform comparison studies [31,37–
38], RT-qPCR is only include for verification thereby not allowing
the full potential of the method in correlation studies between
platforms. This approach may cause significant bias in the data
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e75813
generated as reference genes are required for normalization of the
results. In our study, we profile more than 700 miRNA species by
RT-qPCR and use the complete data set for normalization.
To work out the most reliable strategy for studying miRNA
expression patterns in biological samples, we compare the
performance of different profiling technologies. Breast cancer cell
lines were chosen as a model system since aberrant expression of
several miRNA species in breast tumor tissue has previously been
demonstrated, reflecting the heterogeneous nature of this disease
[39–40]. Recent established profiling platforms within each
technology group were included in the comparison: The nCounter
platform and miRCURY locked nucleic acid (miRCURY) as
representatives for the hybridization and RT-qPCR based
technologies, respectively, and Illumina HiSeq and SOLiD4 as
representatives for the NGS technology. Each platform was
compared and evaluated regarding sensitivity, accuracy, and
flexibility. Compared to previous reports, our study confer
additional strengths to such analyses by (1) including a high
number of miRNAs in all platforms that gives an un-biased robust
sensitivity comparison, (2) using a unique combination of miRNA
profiling platforms, including two NGS platforms in combination
with other profiling technologies and the novel nCounter platform,
(3) giving a deeper analysis of fold change agreement across
platforms, deducting clear guidelines regarding technical accuracy
of observed fold changes, and (4) for all analysis we have adjusted
for the numbers of detected miRNAs in order to give a nonbiased
comparison of platforms. We conclude that cross-platform
comparison studies are important in order to better understand
the nature of the results gained from novel technologies.
Materials and Methods
Cell Cultures
All cell lines were obtained from the American Type Culture
Collection (ATCC) and cultured in a humidified atmosphere at
37uC with 5% CO2. Hs 578T cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) (Life Technologies, Inc)
supplemented with 10% fetal bovine serum (FBS) (EuroClone,
Italy), 2 mM L-glutamine, 0,01 mg/ml insulin, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin (all from Sigma). Hs 578Bst
cells were maintained in Hybri-Care Medium supplemented with
10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 1.5 g/L
sodium bicarbonate, and 30 ng/ml mouse epidermal growth
factor (EGF). AU565 cells were maintained in DMEM, supple-
mented with 10% FBS, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and L-glutamine. SK-BR-3 cells were maintained in
McCoys 5A medium, supplemented with 10% FBS, antibiotics,
and L-glutamine. Cells were propagated in vitro for 5–8 passages
(86106 cells at 80% confluence) prior to total RNA isolation.
Total RNA Isolation and miRNA Enrichment
Total RNA was isolated from 86106 cells using TRIzol (Life
Technologies, Inc), with prolonged precipitation and centrifuga-
tion steps in order to preserve the small RNA fraction. Total RNA
quantification and integrity assessment were performed using
Quant-iT assay (Life Technologies, Inc) and Agilent 2100
Bioanalyzer (Agilent Technologies), respectively. All RNA used
in this study had RNA integrity number (RIN value) above 9.5.
The miRNA fraction was isolated from total RNA samples by
flashPAGETM Fractionator (Life Technologies, Inc) or Pure-
LinkTM miRNA Isolation Kit (Life Technologies, Inc) according to
the manufacturer instructions.
miRCURY LNA Analysis
Approximately 40 ng (per replicate) of total RNA were used for
MiRNA expression quantification using the miRCURY LNATM
Universal RT miRNA PCR system and the miRNA Ready-to-Use
PCR Panels V2M (Exiqon, Denmark) according to the manufac-
turer recommendations. Real time PCR (RT-PCR) amplification
followed by melt curve analysis was carried out on the Applied
Biosystems 7500 RT-PCR platform. Raw Cq values were
calculated with the SDS plate utility software v2.1 (Life
Technologies, Inc) with automatic baseline setting and manual
DRn threshold of 500 for all assays. Amplification curves for every
reaction were manually inspected to confirm log-phase amplifica-
tion. Cq values were adjusted according to interplate calibrators.
Cq values of 36 or higher were set as background (Not Detected),
outliers were manually removed, and fold change analysis where
all performed using Microsoft Excel (Microsoft Corp, Redmond,
WA).
SOLiD4 Next Generation Sequencing Analysis
Approximately 100 ng of small RNA enriched samples were
subjected to adaptor ligation and subsequently cDNA synthesis.
The cDNAs were size selected based on expected size of miRNA
and adaptors (60–80 nt) using NovexH pre-cast gels (Invitrogen).
The purified cDNAs underwent 18 cycles of PCR using barcoded
primers. The PCR products were purified using PureLinkTM PCR
Micro Kit (Invitrogen) and analyzed for size and concentration on
Agilent 2100 Bioanalyzer using DNA 1000 or DNA HS chips.
Equal molar amount of each barcoded sample were pooled
together in one library, which subsequently were used in emulsion
PCR to a total concentration of 0.5 pM. Approximately 650
million enriched beads were deposited on a full glass slide for
SOLiD4 sequencing. The obtained raw color-space data were
analysed in CLC Genomics Workbench (CLCbio, Aarhus Den-
mark). Adaptors were trimmed, sequences were grouped, counted,
and annotated against mature miRNA sequence references.
Successful annotation of a miRNA was stringent and did not
include substitutions or length heteroplasmy. Hence, no isomiRs
were collected. From 192,296,821 raw sequence reads 24,081,459
reads were annotated as mature miRNA species.
Illumina HiSeq Next Generation Sequencing Analysis
Total RNA was shipped to Eurofins MWG operons facility in
Ebersberg, Germany. Barcoded small RNA libraries were created
from 1 ug total RNA according to Illuminas TruSeq small RNA
Sample Preparation Guide. Barcoded pre-trimmed sequences
were imported to CLC Genomic Workbench and followed the
same workflow as for SOLiD sequencing. Here, from 92,961,27
raw sequence reads, 28,885,488 reads were annotated as mature
miRNA species.
All raw sequences (SOLiD and Illumina) were submitted to the
National Center for Biotechnology Information (NCBI) Short
Read Archive, study SRP022047.
NanoString nCounter Analysis
Total RNA (150 ng) was shipped to the NanoString Technol-
ogies facility in Seattle, USA for nCounterH Human miRNA
Expression Assay analysis. RNA was incubated in the presence of
miRNA specific capture and reporter probes, and non-hybridized
probes were removed and the purified hybridized complexes were
immobilized and aligned for data collection as previously reported
[28]. All samples were analysed in triplicates. To account for
minor differences in hybridization and purification efficiencies raw
data was adjusted using a technical normalization factor calculated
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from six internal positive spike controls present in each reaction.
Background hybridization was corrected by deducting the
negative control mean plus two standard deviations calculated
from eight negative controls.
Data Normalization
A significant challenge when analyzing and comparing data is
the difference in output generated by the various platforms.
Therefore the relative expression of combinations of cell lines was
used. Several normalization strategy methods, which including,
global mean normalization [41], quantile normalization [42],
linear total count scaling, and Trimmed Mean of M component
normalization [43], were tested for the different data sets. We,
however, found that implementation of different normalization
strategies for the different platforms had a negative impact on the
concordance between miRNA profiles (data not shown). In order
to reduce normalization based bias we chose a single normaliza-
tion strategy, linear total count scaling, for all four platforms. Since
RT-qPCR operates with logarithmic numbers, normalization was
achieved by linearization of the inverted expression value using the
cut off value as the zero base-line. After normalization RT-qPCR
expression values were converted back into log2 Cq values.
Exact Mature miRNA Sequence Data Base (Exma-miRDB)
In order to compare the results obtained by the PCR,
hybridization, and NGS technologies, we created an in house
reference based on a modified version miRBase v17 that includes
only mature human miRNA sequences. MiRNAs with identical
mature sequence, but originated from different genomic loci, were
merged. Similarly, miRNAs with different sequences but un-
distinguishable in one or more technologies, were also merged.
The hybridization-based nCounter assay included 664 specific
probes for human miRNAs. Some of these targets were in updated
revisions of miRBase found to be obsolete and certain miRNA
species were indistinguishable (e.g. hsa-mir-17 from hsa-mir-106a)
in this technology. Consequently, 33 targets were either merged or
excluded from this panel (Table S1). The prefabricated human
miRNA panels for RT-qPCR contained originally 742 miRNA
specific primers. Here, 20 miRNAs were obsolete and discarded.
The updated screening panels for the four different platforms
targets 631 (nCounter), 722 (miRCURY), and 1719 (SOLiD and
Illumina) miRNAs (Table 1). Out of these, 517 were found to be
concordant and hence preferred in the cross-platform comparison.
However, in individual platform analyses that include technical
correlation studies and side-by-side comparison, all mutual
miRNA targets respective to the platforms in question were
included.
Results
Reference Datasets
In this study three main technologies were used: (1) RT-qPCR
(Exiqon miRCURY LNA), (2) RNA deep sequencing, NGS (Life
Technologies SOLiD4 and Illumina HiSeq), and (3) hybridization
(NanoString nCounter) (Figure 1). In order to compare the
different output formats, a mutual reference database was
generated. Exact mature miRNA sequences were extracted from
the human miRNA database (miRBase v17, http://www.mirbase.
org/) in order to create an in-house local database (Exma-
miRDB). The final Exma-miRDB contained 1719 unique mature
human miRNA sequences.
MiRNA Data Generation
To evaluate the performance of the different technologies,
miRNA expression profiling was carried out on four human breast
cell lines; Hs 578Bst, Hs 578T, SK-BR-3, and AU565. Hs 578T is
a triple-negative basal-like breast cancer cell line originally isolated
from an infiltrating ductal carcinoma. Hs 578Bst was derived from
the same patient, but isolated from normal breast tissue of an
apparent myoepithelial origin. SK-BR-3 and AU565 were
luminal-type breast cancer cell lines derived from a pleural
effusion of a patient with breast carcinoma. Different cell lines
derived from tumorgenic and healthy tissues in the same patient
are of particular interest in miRNA profiling studies, as miRNA
profiles are less biased towards genetic differences. MiRNA
expression profiles were generated for all cell lines using the four
different platforms described above and using the Exma-miRDB
as reference.
Data generated from NGS covered the complete reference of
1719 miRNAs. Here, SOLiD sequencing detected 748 miRNAs in
at least one cell line and 313 in all four cell lines. Corresponding
values for Illumina HiSeq were 630 and 252, respectively. Of the
631 targeted miRNAs in the nCounter assay, 250 miRNAs were
detected in one or more cell lines, while 113 miRNAs were found
in all four cell lines. RT-qPCR quantification detected 424 (one or
more cell line) and 173 miRNAs (all four) out of the 722 different
targets assessed by this platform (Table 1).
Technical reproducibility analyses were carried out for three of
the platforms (miRCURY, nCounter, and SOLiD) by analyzing
linear relationships between all combinations of replicates within
each cell line. Pearson’s correlation analysis revealed a very high
level of reproducibility; R=0.99760.010 (miRCURY, three
replicates), R= 0.99260.008 (nCounter, three replicates), and
R=0.92460.026 (SOLiD, two replicates) (Figure S1). These
datasets, including data from Illumina, were used in the miRNA
expression data comparison to evaluate the performance of the
different platforms in terms of sensitivity, accuracy, and flexibility.
Sensitivity
The sensitivity of a platform was defined as the ability to detect
miRNAs present in a biological sample. The sensitivity is simply
calculated by dividing the number of detected true positive
miRNAs with the total number of true positive miRNAs in a
sample. Since the investigated biological samples were isolates
from cell lines, and not synthetic miRNA species, the true miRNA
counts in our samples were unknown. Therefore, to calculate the
sensitivity a miRNA was defined as a true positive if at least three
out of the four platforms identified the miRNA, and as a true
negative/absent if identified by only two or less platforms. MiRNA
profiles generated from all cell lines were used, but only miRNAs
screened for in all platforms (517) were included in the
comparison. Using the 517 concordant miRNAs and the four cell
Table 1. Platform screening potential.
Targeted
miRNAs
Observed
miRNA
Percentage of
reference
SOLiD 1719 748 (44%) 44%
Illumina 1719 630 (37%) 37%
nCounter 631 250 (40%) 15%
miRCURY 722 424 (59%) 24%
The theoretical number of possible miRNAs detected within each technology is
compared to the observed number found in this study. IsomiRs are not
included.
doi:10.1371/journal.pone.0075813.t001
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lines gave rise to a total of 2068 miRNA data points in the
sensitivity analysis. Out of these 777 miRNAs (38%) were regarded
as true positive based on the above-mentioned criteria. Here, 763
and 764 were detected by the NGS platforms resulting in a
sensitivity rating as high as 0.982 and 0.983, SOLiD and Illumina,
respectively (Table S2). miRCURY (RT-qPCR) came close to the
NGS platforms with a sensitivity of 0.959 (745 detected). nCounter
(hybridization), on the contrary, detected only 501 of the miRNAs,
which gave a sensitivity of 0.645.
The degree of convergence between each platform was then
examined (Figure 2A). We found 442 miRNAs to be detected by
all four platforms in the four cell lines. Additionally, 910 miRNAs
throughout the cell lines were detected by at least one single
platform. The percentile distributions of the individual miRNAs
within these two subsets were grouped according to their
individual concentration. Not surprisingly, the expression percen-
tile distribution clearly illustrated the correlation of individual
miRNA sample concentration and the ability to be identified by
the various platforms. The majority of miRNAs detected by only a
single platform were expressed at low levels, whereas the majority
of highly expressed miRNAs were detected by all four platforms
(Figures 2B and 2C). This is consistent with a postulate that the
probability to be detected by the various platforms is higher for an
extensively expressed miRNA than from a scarcely expressed
miRNA. In addition, the probability of an expressed miRNA to be
a false positive decrease as other platforms detects the same
miRNA. Together, these two postulations were used to create a
new weighted sensitivity comparison. Here, a highly expressed
miRNA detected by several of the platforms generated a higher
score, (positive if it were detected by both platforms, and negative
if it were only detected by one of the platforms), than a scarcely
expressed miRNA detected by few platforms. To overcome the
problem of having to create a hypothetical list of true and false
miRNAs in our samples, two and two platforms were grouped in
order to evaluate the sensitivity in pairs. The calculation was done
accordingly: 1) All miRNA were used to assess if the pair under
investigation detected the miRNA or not. If both members
identified the same miRNA it was given a positive value. In
contrast, if only one member detected the miRNA, it was given a
negative value. 2) The score was weighted in accordance to the
expression of the miRNA and in accordance to detection of the
miRNA by the two other platforms not under investigation. 3) The
total score was scaled in order to compare the different pair
combinations; a score of 21.000 corresponds to no commonly
detected miRNAs, while a score of 1.000 were given if both team
members detected the exact same set of miRNAs.
The result shows that every time nCounter is teamed up with
another platform, the sensitivity falls below the average of all
sensitivity comparisons. In contrast, all of the other platforms
perform very well in other pair conformation; the best being the
two NGS platforms (SOLiD and Illumina), followed by any
combinations of NGS and miRCURY (Table 2).
Accuracy
The accuracy of a platform was defined as the ability of the
platform to correctly identify fold change differences in biological
samples. In order to evaluate the accuracy, the relative expression
levels of miRNAs using all six combinations of the four cell lines
were included. For assessment of the accuracy, pairs of platforms
were compared. We found that for most miRNAs (average of
83%) the pattern of expression (up- or down-regulated) was
similar, but the relative amplitude of the fold changes varied
according to the different platforms being used.
Pearson’s correlation (R) was used to calculate the accuracy
across platforms. R-values were in accordance to the calculation
on the pattern of expression, and showed that the overall
correlation for all platforms was high (P= 0.703–0.797)
(Figure 3). However, we were not able to identify a specific pair
Figure 1. Project design. Relevant figure and table references are
noted. Human breast cell lines were cultured and total RNA was
extracted. MiRNA profiles were obtained using four different platforms;
Exiqon miRCURY LNA, Life Technologies SOLiD4, Illumina HiSeq, and
NanoString nCounter. A local miRNA database (Exma-miRDB) was
generated based on mature sequences found in miRBase v17. The
performances of the platforms were evaluated in regards to accuracy,
sensitivity, and flexibility.
doi:10.1371/journal.pone.0075813.g001
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of platforms as significantly better than any of the other
combinations of platforms. These results are in accordance with
previously published platform comparison performances [31–
32,44–46]. We further noted that the number of data points
included in the correlation differed significantly between the
technologies, from 516 (miRCURY/nCounter) to 1545 (SOLiD/
Illumina). These differences were not only due to the limited
number of primers and probes in the miRCURY or nCounter
panels, but were also a result of the ability of NGS to identify more
miRNAs in general, as seen by the sensitivity comparison (Table 2,
Figure S2).
Figure 2. Platform sensitivity. (A) Venn diagram displaying the convergence of detected miRNAs by the four platforms. Dispersion of the
concentration of individual miRNAs detected by a single platform (B) and all platforms (C). The miRNAs are grouped in accordance to the percentile
distribution, where the 20% lowest expressed miRNAs within a platform are grouped, the miRNAs with an expression between the 20% lowest and
the 40% lowest are grouped, and so on.
doi:10.1371/journal.pone.0075813.g002
Table 2. Platform sensitivity.
nCounter paired
miRCURY
nCounterpaired
SOLiD
nCounterpaired
Illumina
miRCURY paired
SOLiD
miRCURY paired
Illumina
SOLiD paired
Illumina
miRNA detected in a single
platform
581 690 606 427 345 312
…no additional platforms (2) 166 222 140 204 122 178
…one additional platform (22) 107 178 177 177 178 107
…two additional platforms (222) 308 290 289 46 45 27
miRNA detected in both
platforms
483 508 494 779 764 860
…only these two platforms (+) 14 21 6 48 32 110
…one additional platform (++) 27 45 46 289 290 308
…two additional platforms (+++) 442 442 442 442 442 442
% miRNA detected by both
platforms
45% 42% 45% 65% 69% 73%
Weighted score 0.31 0.30 0.31 0.74 0.75 0.83
For each combination of platforms the identified miRNAs were used to calculate a weighted detection score based on the concordance of the two platforms (noted by
‘‘+’’ and ‘‘2’’). The score took into account both the expression value of the individual miRNAs and detection by the other platforms that were not under investigation.
The weighted score range from 21.0 (no agreement) to 1.0 (full agreement). Only miRNAs screened for in all platforms were included.
doi:10.1371/journal.pone.0075813.t002
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To further examine the accuracy, the fold change in relation to
miRNA expression was investigated. The accuracy was found to
be constant across the concentration of individual miRNAs for the
NGS platforms and for miRCURY (Figure 4A), with an average
of 81% 62%. A higher variation was seen for the comparisons
including the nCounter platform (82% 66%), with the accuracy
being proportional with increasing miRNA sample concentration
(Figure 4B).
Platform dependent differences were not identified when
analyzing the data in accordance to fold change value, but a
general trend was seen for all platforms. If the change was three
fold or more it was only a 2% likelihood of the fold change to be
contradictable when comparing the platforms in pairs (Figure 5,
Paired). However, if the fold change was close to one, 30% of fold
changes were found to be contradictory (Figure 5, Paired). When
exclusively examining the fold changes for miRNAs that were
mutually detected by all four platforms (AP) (Figure 5, AP, Figure
S2), nearly half (47%) of the miRNAs with an average fold change
close to one had at least one platform showing a contradictory fold
change. In contrast, all platforms were in agreement if changes
were above three fold. Thus, we conclude that the probability of
correctly identifying a true difference in expression increases with
the level of fold change.
Flexibility
The flexibility of a platform reflects its ability to serve additional
functions to the data collected. In this context, there are several
reasons for why we find NGS technology far more versatile than
RT-qPCR and hybridization based technologies. (i) In profiling,
NGS has the advantage of being the only technology that uses the
complete reference dataset. (ii) NGS is collecting data of miRNA
species not yet discovered or annotated in the reference data base.
RT-qPCR and hybridization technologies, however, are restricted
to pre-designed primers and probes combinations, and (iii) due to
the single nucleotide resolution of the NGS platforms, additional
level of information is collected in both length and site
heteroplasmy for each miRNA (isomiRs). By a simple search in
our SOLiD and Illumina datasets, we found approximately the
same number of isomiRs reads as mature miRNAs reads (Table
S3). We also find that sequences annotated as isomiRs behaved in
a similar manner as sequences annotated as canonical mature
sequences in regards to accuracy (Figure S3).
Discussion
Performance Evaluation
The strength and limitations for the main miRNA profiling
technologies, as well as for the individual commercial vendors,
have been thoroughly reviewed in [25]. In this work, however, we
challenge their conclusion regarding that RT-qPCR has a better
sensitivity than NGS. The two NGS platforms were here found to
have the highest sensitivity score. This was due to the fact that they
detected the highest number of miRNAs, which are likely to be
true positives as these miRNAs were also found to be expressed by
Figure 3. Fold change scatterplot. The miRNA fold change values are plotted for every combination of platforms. Fold change values were log2
transformed and Pearson’s correlation (R) was used to assess the accuracy. Confidence limits are included in brackets. Number of miRNA included in
the calculation (n). Asterisk (*) indicate p-value ,0,0001.
doi:10.1371/journal.pone.0075813.g003
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additional platforms. miRCURY also performed very well, and
when combined with the NGS platforms no obvious preference for
either SOLiD or Illumina could be observed. Surprisingly, in
contrast to NGS and miRCURY, the nCounter system was found
to have a low sensitivity. nCounter is a hybridization based
technology and the only platform in our study lacking an
amplification step. This may reduce the window between a true-
positive miRNA expression and the background, which thereby
accounts for at least some of the reduction in the sensitivity. This
was clearly visualized in the Venn diagram presented in Figure 2.
Here, miRCURY and the two NGS platforms detect 276
miRNAs, which were not identified by nCounter, a number that
is about half of the miRNAs detected by all four platforms (442
miRNAs). Hybridization based technologies, in general, have
limitations in distinguishing between highly similar target
sequences [47]. Indeed nCounter has this limitation as well,
particularly if the dissimilarity is located at the 59 end of the
miRNA. As for miRNA profiling there are lots of miRNA species
with only one nucleotide difference, including the highly cancer
relevant hsa-miR-17 and hsa-miR-106 (see Table S1). However, in
projects that involve large sample size and limited number of
highly expressed non-merged miRNAs, we find the nCounter
system to be highly capable due to its short hands-on time [25].
The accuracy was found to be similar for all combinations of the
four platforms. A slightly, but not significantly, better correlation
was seen for the nCounter system in combination with miRCURY
and for the combination of the two NGS platforms SOLiD and
Illumina. This could be due to a more similar library preparation
protocol between these platforms, which would be in accordance
to previous reports that library preparation method, and not the
sequencing platforms, appears crucial in miRNA expression
profiles [34,36–37]. One of these studies also concluded that
different library preparation methods gave different expression
ranks for the miRNAs detected [34]. Thus, the absolute expression
level cannot exactly be determent for any of the platforms. The
difference in miRNA rank outcome from library preparation will
not however affect the fold change as the same bias is introduced
for both the control and test sample. Here we show that the
accuracy of NGS and miRCURY is close to constant across the
individual miRNA concentrations (Figure 4). This means that in a
fold change comparisons there is not necessary to discard scarcely
expressed miRNAs involved in large fold changes as it is the
change itself and not the individual expressions that are
comparable across platforms. However, the expression levels will
affect the probability for detecting the miRNA by a different
platform. This is highly important in verification studies where
miRNAs that do not have large fold changes or are highly
expressed may fail verification.
When is a miRNA gene differentially expressed? A common
practice in profiling studies is to score a miRNA as differentially
expressed if the miRNA level shows change above two fold. This
Figure 4. Platform accuracy in relation to miRNA concentration. (A) The percent identity in fold change across the percentile distribution of
miRNAs for all platform combinations without the nCounter platform. Here, an even accuracy is seen across the full range of miRNA concentration.
(B) The same data for platform combinations involving the nCounter platform reveal a large drop in accuracy when the miRNA abundance is low.
doi:10.1371/journal.pone.0075813.g004
Figure 5. Platform accuracy across fold change level. Percent
identity across the fold change level for every combination of platforms
(Paired) and for miRNAs only mutually detected by all platforms (AP).
doi:10.1371/journal.pone.0075813.g005
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threshold might be sufficient to hide biological significant
differences. However, due to technical limitations of profiling
technologies and due to normal biological variations, this
threshold might in fact also be too low in order to avoid false
positive. We tested for normal variation by performing an
additional independent experiment that included a biological
replicate of the Hs 578T cell line. Here, we detected a median
fluctuation of 2.6 fold change between identical miRNA when
compared to our original sequencing experiment (Table S4).
These data are supported by the observation of 2–4 fold random
fluctuations for many genes in yeast [48,49]. In our study, we see a
technical agreement of only 81% at a fold change level below two
fold. We therefore conclude based on the combination of both
technical and biological variations that required level of fold
change should be increased to a change of at least 3–4 fold for a
miRNA to be defined as differentially expressed.
Only NGS platforms are able to detect isomiRs. Based on our
data analysis of the four cell lines, the abundance of isomiRs is
about equal to the amount of mature sequences (Table S3). As
more NGS miRNA profiling studies are being performed, the
mature sequences of present known miRNAs will probably be
redefined when isomiRs are discovered to be more dominantly
expressed than the canonical miRNA. The role of isomiRs has still
not been unraveled, but an increasingly number of recent reports
suggests important new and distinct functions for the isomeric
miRNAs compared to their canonical counterparts [50,51]. In this
study we build up on the statement of isomiR being real miRNA
variants and not sequencing errors by showing a similar behavior
for isomiRs and conical miRNAs in regards to profiling accuracy
for SOLiD and Illumina.
Concluding Remarks
Based on the sensitivity and accuracy obtained in this study of
the different platforms, we recommend an initial miRNA profiling
based on NGS or RT-qPCR. Furthermore, NGS has additional
strengths in regards to the flexibility, and the SOLiD and Illumina
platforms perform equally well. Recent developments in NGS
technologies have lowered the cost and hands-on time of high-
throughput profiling to a level comparable to RT-qPCR. These
considerations give in our view NGS an important advantage in
miRNA profiling. Regardless of the technology or platform used,
we strongly recommend that biological relevant miRNA should be
verified by an independent platform, and that expression
differences should be supported by a high fold change.
Supporting Information
Figure S1 Technical replicate scatter plots. The combi-
nations of every technical replicates were used to create the
scatterplot. Correlation coefficients were calculated using Pear-
son’s correlation (R). MiRNA replicates with a fold change
difference .2 are colored red. (A) miRCURY, three replicates
(4263 data points), (B) nCounter, three replicates (2491 data
points), (C) SOLiD, two replicates (1876 data points).
(TIF)
Figure S2 Heat map of miRNAs detected in all four
platforms. Only the relative expressions found in all platforms
from the combination of the cell line Hs 578Bst versus Hs 578T
are shown. Fold change values are log2 transformed, and miRNAs
are clustered according to hclust function (R-package). (A)
Histogram showing the fold change distribution. (B) Green color
represent a downregulation in Hs 578T compared to Hs 578Bst,
and red color represent an upregulation in Hs 578T compared to
Hs 578Bst. Hierarchical clustering was performed to display the
data. Differentially expressed miRNAs that were reported by all
platforms (.3 fold) are marked in bold.
(TIF)
Figure S3 Next generation sequencing platform accura-
cy for canonical miRNAs versus isomiR. The miRNA fold
change values are plotted for the combination of SOLiD and
Illumina for (A) canonical miRNAs and (B) isomiRs. Fold change
values were log2 transformed and Pearson’s correlation (R) was
used to assess the accuracy. Confidence limits are included in
brackets. Number of miRNA included in the calculation (n).
Asterisk (*) indicate p-value ,0,0001. Platform accuracy in
relation to miRNA concentration for the combination of SOLiD
and Illumina for (C) canonical miRNAs and (D) isomiRs. The
percent identity in fold change is plotted across the percentile
distribution of miRNAs. Platform accuracy across fold change
level for the combination of SOLiD and Illumina for (E) canonical
miRNAs and (F) isomiRs.
(TIF)
Table S1 miRCURY and nCounter panlels updated according
to miRBase v17. Changes are synchronized with the local miRNA
database (Exma-miRDB).
(PDF)
Table S2 Sensitivity and specificity calculation. A positive
miRNA was defined as a miRNA that were detected by at least
3 platforms. In total 777 miRNAs were defined as true positive
and 1291 miRNAs were defined as true negatives. Only miRNAs
screened for in all platforms were included. (A) nCounter, (B),
miRCURY, (C) SOLiD, (D) Illumina, (E) Sensitivity and
Specificity calculation.
(PDF)
Table S3 IsomiR quantitated in NGS data. NGS data were
mapped against Exma-miRDB (includes only the mature miRNA
sequences in miRBase v17), as well as the hairpin sequences of all
annotated miRNA in miRBase v17. Both sets of NGS data
generated from Illumina and SOLiD were used for isomiR
quantification.
(PDF)
Table S4 MicroRNA profile of two biological replicates using
SOLiD sequencing. Values are log2 transformed and the
differences are presented as absolute fold change values.
(PDF)
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